These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 16462755

  • 1. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development.
    Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A.
    Bone Marrow Transplant; 2006 Mar; 37(6):539-46. PubMed ID: 16462755
    [Abstract] [Full Text] [Related]

  • 2. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 3. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J, Einsele H, Gil L, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [Abstract] [Full Text] [Related]

  • 4. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C, Giacchino F, Bergallo M, Bonello F, Bollero C, Segoloni GP, Cavallo R.
    G Ital Nefrol; 2003 Oct; 20(2):170-5. PubMed ID: 12746803
    [Abstract] [Full Text] [Related]

  • 5. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
    Merlino C, Cavallo R, Bergallo M, Giacchino F, Bollero C, Negro Ponzi A, Cavallo G.
    New Microbiol; 2003 Apr; 26(2):141-9. PubMed ID: 12737195
    [Abstract] [Full Text] [Related]

  • 6. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA.
    Clin Transplant; 2006 Apr; 20(3):389-93. PubMed ID: 16824159
    [Abstract] [Full Text] [Related]

  • 7. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K.
    Scand J Infect Dis; 2007 Apr; 39(3):235-44. PubMed ID: 17366054
    [Abstract] [Full Text] [Related]

  • 8. Early evidence of lymphoproliferative disorder: post-transplant monitoring of Epstein-Barr infection in adult and pediatric patients.
    Gaeta A, Nazzari C, Verzaro S, Latte MC, Fabri G, Scateni S, Raggi C, Lubrano R, Mancini C.
    New Microbiol; 2006 Oct; 29(4):231-41. PubMed ID: 17201089
    [Abstract] [Full Text] [Related]

  • 9. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
    Greenfield HM, Gharib MI, Turner AJ, Guiver M, Carr T, Will AM, Wynn RF.
    Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207
    [Abstract] [Full Text] [Related]

  • 10. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M, Le Blanc K, Ringdén O, Barkholt L, Omazic B, Lergin C, Levitsky V, Remberger M.
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [Abstract] [Full Text] [Related]

  • 11. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F.
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [Abstract] [Full Text] [Related]

  • 12. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.
    Ahmad I, Cau NV, Kwan J, Maaroufi Y, Meuleman N, Aoun M, Lewalle P, Martiat P, Crokaert F, Bron D.
    Transplantation; 2009 Apr 27; 87(8):1240-5. PubMed ID: 19384173
    [Abstract] [Full Text] [Related]

  • 13. Quantification of Epstein-Barr virus load in Argentinean transplant recipients using real-time PCR.
    Yancoski J, Danielian S, Ibañez J, Turconi A, Cuarterolo M, Zelazko M, Niesters Hubert GM.
    J Clin Virol; 2004 Sep 27; 31(1):58-65. PubMed ID: 15288615
    [Abstract] [Full Text] [Related]

  • 14. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
    Meerbach A, Wutzler P, Häfer R, Zintl F, Gruhn B.
    J Med Virol; 2008 Mar 27; 80(3):441-54. PubMed ID: 18205222
    [Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
    Garceau P, Couture C, Cantin B, Bernier V, Sénéchal M.
    J Heart Lung Transplant; 2008 Aug 27; 27(8):928-31. PubMed ID: 18656811
    [Abstract] [Full Text] [Related]

  • 16. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Clin Infect Dis; 2013 Sep 27; 57(6):794-802. PubMed ID: 23771985
    [Abstract] [Full Text] [Related]

  • 17. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH, Russ GR, Coates PT.
    Nephrology (Carlton); 2006 Aug 27; 11(4):355-66. PubMed ID: 16889577
    [Abstract] [Full Text] [Related]

  • 18. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 27; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 19. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.
    Leung E, Shenton BK, Green K, Jackson G, Gould FK, Yap C, Talbot D.
    Transpl Infect Dis; 2004 Dec 27; 6(4):156-64. PubMed ID: 15762933
    [Abstract] [Full Text] [Related]

  • 20. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease.
    Carpentier L, Tapiero B, Alvarez F, Viau C, Alfieri C.
    J Infect Dis; 2003 Dec 15; 188(12):1853-64. PubMed ID: 14673764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.